60 subjects randomized 1:1:1 and treated with IVT Fovista® 1.5 mg/eye in combination with anti-VEGF therapy as follows:~Avastin® 1.25 mg/eye (20 subjects)~Lucentis® 0.5 mg/eye (20 subjects)~Eylea® 2.0 mg/eye (20 subjects)~Subjects will be stratified by lesion size (≤2 DA vs. >2 DA).~Subjects will be treated with combination therapy of IVT Fovista® and IVT anti-VEGF therapy every month for the first 5 months (Day 1, Months 1,2,3,4), followed by Q12W (every 12 weeks) administration (Months 7,10, 13,16, 19 and 22), for a total of 24 months.~When administered, IVT Fovista® will be given first, followed by IVT anti-VEGF (same day).
To evaluate the safety of intravitreal (IVT) Fovista® administered in combination with anti-VEGF therapy.